Wall Street analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to report $2.26 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Ascendis Pharma A/S’s earnings, with the lowest sales estimate coming in at $1.52 million and the highest estimate coming in at $2.77 million. Ascendis Pharma A/S posted sales of $12.00 million in the same quarter last year, which would indicate a negative year over year growth rate of 81.2%. The company is scheduled to issue its next quarterly earnings report on Wednesday, April 1st.
According to Zacks, analysts expect that Ascendis Pharma A/S will report full-year sales of $14.00 million for the current year, with estimates ranging from $12.08 million to $15.07 million. For the next fiscal year, analysts anticipate that the business will post sales of $6.93 million, with estimates ranging from $1.12 million to $15.29 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Ascendis Pharma A/S.
Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Monday, November 18th. The biotechnology company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.78. Ascendis Pharma A/S had a negative return on equity of 29.04% and a negative net margin of 789.80%. The company had revenue of $2.49 million during the quarter, compared to analyst estimates of $1.88 million.
ASND has been the subject of a number of research reports. Zacks Investment Research lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Morgan Stanley increased their price target on Ascendis Pharma A/S from $134.00 to $140.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. ValuEngine lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. Leerink Swann reissued an “outperform” rating and set a $152.00 price target (up from $140.00) on shares of Ascendis Pharma A/S in a research note on Tuesday, December 3rd. Finally, BidaskClub raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, December 25th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $152.00.
A number of hedge funds have recently modified their holdings of the business. Voloridge Investment Management LLC raised its position in Ascendis Pharma A/S by 1,076.9% during the third quarter. Voloridge Investment Management LLC now owns 24,361 shares of the biotechnology company’s stock valued at $2,346,000 after purchasing an additional 22,291 shares during the period. Castleark Management LLC raised its position in Ascendis Pharma A/S by 15.4% during the third quarter. Castleark Management LLC now owns 4,730 shares of the biotechnology company’s stock valued at $456,000 after purchasing an additional 630 shares during the period. Barclays PLC raised its position in Ascendis Pharma A/S by 2,789.6% during the third quarter. Barclays PLC now owns 8,611 shares of the biotechnology company’s stock valued at $829,000 after purchasing an additional 8,313 shares during the period. Stifel Financial Corp raised its position in Ascendis Pharma A/S by 62.5% during the third quarter. Stifel Financial Corp now owns 4,203 shares of the biotechnology company’s stock valued at $407,000 after purchasing an additional 1,616 shares during the period. Finally, State Street Corp raised its position in Ascendis Pharma A/S by 3.9% during the third quarter. State Street Corp now owns 9,352 shares of the biotechnology company’s stock valued at $901,000 after purchasing an additional 352 shares during the period.
Ascendis Pharma A/S stock traded up $1.25 during midday trading on Monday, reaching $140.45. 5,726 shares of the stock traded hands, compared to its average volume of 227,106. The stock’s fifty day moving average is $125.66 and its 200-day moving average is $113.44. Ascendis Pharma A/S has a 12 month low of $66.11 and a 12 month high of $142.94. The stock has a market cap of $5.85 billion, a P/E ratio of -37.55 and a beta of 0.67. The company has a quick ratio of 15.75, a current ratio of 15.74 and a debt-to-equity ratio of 0.05.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Read More: What are no-load funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.